You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNisoldipine
Accession NumberDB00401  (APRD00635)
TypeSmall Molecule
GroupsApproved
DescriptionNisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Structure
Thumb
Synonyms
isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Nisoldipin
Nisoldipina
Nisoldipine
Nisoldipino
Nisoldipinum
Sular
External Identifiers
  • Bay K 5552
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nisoldipinetablet, film coated, extended release8.5 mg/1oralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
Nisoldipinetablet, film coated, extended release8.5 mg/1oralPrasco Laboratories2012-02-27Not applicableUs
Nisoldipinetablet, film coated, extended release17 mg/1oralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
Nisoldipinetablet, film coated, extended release17 mg/1oralPrasco Laboratories2012-02-27Not applicableUs
Nisoldipinetablet, film coated, extended release25.5 mg/1oralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
Nisoldipinetablet, film coated, extended release34 mg/1oralPrasco Laboratories2012-02-27Not applicableUs
Nisoldipinetablet, film coated, extended release34 mg/1oralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
Sulartablet, film coated, extended release34 mg/1oralShionogi Inc.1995-02-02Not applicableUs
Sulartablet, film coated, extended release25.5 mg/1oralPhysicians Total Care, Inc.2009-02-24Not applicableUs
Sulartablet, film coated, extended release8.5 mg/1oralShionogi Inc.1995-02-02Not applicableUs
Sulartablet, film coated, extended release17 mg/1oralShionogi Inc.1995-02-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nisoldipinetablet, film coated, extended release40 mg/1oralPhysicians Total Care, Inc.2008-08-29Not applicableUs
Nisoldipinetablet, film coated, extended release8.5 mg/1oralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
Nisoldipinetablet, film coated, extended release20 mg/1oralMylan Pharmaceuticals Inc.2008-07-25Not applicableUs
Nisoldipinetablet, film coated, extended release17 mg/1oralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
Nisoldipinetablet, film coated, extended release30 mg/1oralMylan Pharmaceuticals Inc.2008-07-25Not applicableUs
Nisoldipinetablet, film coated, extended release25.5 mg/1oralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
Nisoldipinetablet, film coated, extended release40 mg/1oralMylan Pharmaceuticals Inc.2008-07-25Not applicableUs
Nisoldipinetablet, film coated, extended release34 mg/1oralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BaymycardBayer
Baymycard RRBayer
Bo PingRui Yang Pharm
Di Yi XinTasly
Ji Ni Le ErJiankang Pharmaceutical
NinobarucinChoseido Pharmaceutical
NisomynardYoshindo
RiohardTaiyo Pharmaceutical
RuidiNanjing Sanrui Pharmaceutical Co.
SyscorBayer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4I8HAB65SZ
CAS number63675-72-9
WeightAverage: 388.4144
Monoisotopic: 388.16343651
Chemical FormulaC20H24N2O6
InChI KeyInChIKey=VKQFCGNPDRICFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
IUPAC Name
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
PharmacodynamicsNisoldipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Related Articles
AbsorptionRelatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%.
Volume of distributionNot Available
Protein binding99%
Metabolism

Pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4.

Route of eliminationAlthough 60-80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine.
Half life7-12 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nisoldipine Action PathwayDrug actionSMP00381
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9357
Blood Brain Barrier-0.947
Caco-2 permeable+0.6928
P-glycoprotein substrateSubstrate0.5548
P-glycoprotein inhibitor IInhibitor0.8824
P-glycoprotein inhibitor IIInhibitor0.9239
Renal organic cation transporterNon-inhibitor0.8925
CYP450 2C9 substrateNon-substrate0.7874
CYP450 2D6 substrateNon-substrate0.8929
CYP450 3A4 substrateSubstrate0.7366
CYP450 1A2 substrateInhibitor0.8782
CYP450 2C9 inhibitorInhibitor0.7826
CYP450 2D6 inhibitorNon-inhibitor0.9141
CYP450 2C19 inhibitorInhibitor0.7804
CYP450 3A4 inhibitorInhibitor0.8414
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8982
Ames testNon AMES toxic0.778
CarcinogenicityNon-carcinogens0.5782
BiodegradationNot ready biodegradable0.9335
Rat acute toxicity2.6277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.9175
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mylan pharmaceuticals inc
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseoral17 mg/1
Tablet, film coated, extended releaseoral20 mg/1
Tablet, film coated, extended releaseoral25.5 mg/1
Tablet, film coated, extended releaseoral30 mg/1
Tablet, film coated, extended releaseoral34 mg/1
Tablet, film coated, extended releaseoral40 mg/1
Tablet, film coated, extended releaseoral8.5 mg/1
Prices
Unit descriptionCostUnit
Sular 25.5 mg 24 Hour tablet6.84USD tablet
Sular 34 mg 24 Hour tablet6.84USD tablet
Sular 17 mg 24 Hour tablet6.48USD tablet
Sular 34 mg tablet5.64USD tablet
Sular 17 mg tablet5.17USD tablet
Nisoldipine er 30 mg tablet5.07USD tablet
Nisoldipine er 40 mg tablet5.07USD tablet
Sular 10 mg tablet5.04USD tablet
Sular 8.5 mg 24 Hour tablet5.04USD tablet
Nisoldipine er 20 mg tablet4.65USD tablet
Sular 25.5 mg tablet4.35USD tablet
Sular 8.5 mg tablet4.13USD tablet
Sular 20 mg tablet3.37USD tablet
Sular 30 mg 24 Hour tablet3.23USD tablet
Sular 40 mg 24 Hour tablet3.23USD tablet
Sular 30 mg tablet3.1USD tablet
Sular 40 mg tablet2.61USD tablet
Sular 10 mg 24 Hour tablet2.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5422123 No1995-06-062012-06-06Us
US5626874 No1994-11-302014-11-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.26MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00577 mg/mLALOGPS
logP3.63ALOGPS
logP3.06ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)5.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity105.91 m3·mol-1ChemAxon
Polarizability39.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Massimo Ferrari, Marcello Ghezzi, Manuel Alberelli, Alberto Ambrosini, “Industrial process for the synthesis of isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate (nisoldipine).” U.S. Patent US20050240022, issued October 27, 2005.

US20050240022
General References
  1. Mielcarek J, Grobelny P, Szamburska O: The effect of beta-carotene on the photostability of nisoldipine. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):167-71. [PubMed:15834448 ]
  2. Missan S, Zhabyeyev P, Dyachok O, Jones SE, McDonald TF: Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br J Pharmacol. 2003 Nov;140(5):863-70. Epub 2003 Oct 6. [PubMed:14530219 ]
  3. Hamilton SF, Houle LM, Thadani U: Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure. Heart Dis. 1999 Nov-Dec;1(5):279-88. [PubMed:11720635 ]
External Links
ATC CodesC08CA07
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nisoldipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nisoldipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nisoldipine.
AcebutololNisoldipine may increase the hypotensive activities of Acebutolol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nisoldipine.
AcetazolamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nisoldipine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nisoldipine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nisoldipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nisoldipine.
AliskirenNisoldipine may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nisoldipine.
AlprenololNisoldipine may increase the hypotensive activities of Alprenolol.
AmbrisentanNisoldipine may increase the hypotensive activities of Ambrisentan.
AmifostineNisoldipine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amiloride.
AmiodaroneThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nisoldipine.
AmlodipineAmlodipine may increase the hypotensive activities of Nisoldipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Nisoldipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nisoldipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nisoldipine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nisoldipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nisoldipine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nisoldipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Apraclonidine.
AprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the hypotensive activities of Nisoldipine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nisoldipine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nisoldipine.
AtazanavirThe serum concentration of Nisoldipine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Nisoldipine.
AtomoxetineThe metabolism of Nisoldipine can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Atosiban.
Atracurium besylateNisoldipine may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nisoldipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Azilsartan medoxomil.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nisoldipine.
BarbitalBarbital may increase the hypotensive activities of Nisoldipine.
BenazeprilNisoldipine may increase the hypotensive activities of Benazepril.
BendroflumethiazideNisoldipine may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Nisoldipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nisoldipine.
BepridilNisoldipine may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nisoldipine.
BetaxololBetaxolol may increase the hypotensive activities of Nisoldipine.
BethanidineBethanidine may increase the hypotensive activities of Nisoldipine.
BexaroteneThe serum concentration of Nisoldipine can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nisoldipine.
BimatoprostNisoldipine may increase the hypotensive activities of Bimatoprost.
BisoprololNisoldipine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Nisoldipine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Nisoldipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nisoldipine can be decreased when it is combined with Bosentan.
BosentanNisoldipine may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nisoldipine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.
BretyliumNisoldipine may increase the hypotensive activities of Bretylium.
BrimonidineNisoldipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Nisoldipine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nisoldipine.
BumetanideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.
BupranololNisoldipine may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nisoldipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nisoldipine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nisoldipine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Nisoldipine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nisoldipine.
CanagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Canagliflozin.
CandesartanNisoldipine may increase the hypotensive activities of Candesartan.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nisoldipine.
CandoxatrilNisoldipine may increase the hypotensive activities of Candoxatril.
CaptoprilNisoldipine may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nisoldipine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nisoldipine.
CaroxazoneCaroxazone may increase the hypotensive activities of Nisoldipine.
CarteololNisoldipine may increase the hypotensive activities of Carteolol.
CarvedilolNisoldipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nisoldipine.
CeliprololNisoldipine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Nisoldipine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nisoldipine.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nisoldipine.
ChlorothiazideNisoldipine may increase the hypotensive activities of Chlorothiazide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nisoldipine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Nisoldipine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nisoldipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nisoldipine.
CilazaprilNisoldipine may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nisoldipine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nisoldipine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nisoldipine.
ClarithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Nisoldipine can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nisoldipine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nisoldipine.
ClonidineNisoldipine may increase the hypotensive activities of Clonidine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine.
ClotrimazoleThe metabolism of Nisoldipine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Nisoldipine.
CobicistatThe serum concentration of Nisoldipine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nisoldipine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nisoldipine.
ConivaptanThe serum concentration of Nisoldipine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nisoldipine.
CrizotinibThe metabolism of Nisoldipine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nisoldipine.
CryptenamineNisoldipine may increase the hypotensive activities of Cryptenamine.
CyclosporineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nisoldipine.
CyclothiazideNisoldipine may increase the hypotensive activities of Cyclothiazide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nisoldipine.
DabrafenibThe serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Nisoldipine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nisoldipine.
DapagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nisoldipine.
DarunavirThe serum concentration of Nisoldipine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nisoldipine.
DebrisoquinNisoldipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nisoldipine.
DeferasiroxThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nisoldipine can be decreased when combined with Delavirdine.
DeserpidineNisoldipine may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Nisoldipine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nisoldipine.
DiazoxideDiazoxide may increase the hypotensive activities of Nisoldipine.
DiclofenamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nisoldipine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nisoldipine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nisoldipine.
DihydroergotamineThe metabolism of Nisoldipine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nisoldipine.
DiltiazemDiltiazem may increase the hypotensive activities of Nisoldipine.
DinutuximabThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nisoldipine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nisoldipine.
DorzolamideNisoldipine may increase the hypotensive activities of Dorzolamide.
DoxazosinNisoldipine may increase the hypotensive activities of Doxazosin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nisoldipine.
DoxycyclineThe metabolism of Nisoldipine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Nisoldipine can be decreased when combined with Dronedarone.
DuloxetineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nisoldipine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nisoldipine.
EfavirenzThe serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nisoldipine.
EfonidipineNisoldipine may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nisoldipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.
EnalaprilNisoldipine may increase the hypotensive activities of Enalapril.
EnalaprilatNisoldipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nisoldipine.
EplerenoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eplerenone.
EpoprostenolNisoldipine may increase the hypotensive activities of Epoprostenol.
EprosartanNisoldipine may increase the hypotensive activities of Eprosartan.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nisoldipine.
ErythromycinThe metabolism of Nisoldipine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Nisoldipine.
Eslicarbazepine acetateThe serum concentration of Nisoldipine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nisoldipine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nisoldipine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Nisoldipine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Nisoldipine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nisoldipine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nisoldipine.
EtravirineThe serum concentration of Nisoldipine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nisoldipine.
FelodipineNisoldipine may increase the hypotensive activities of Felodipine.
FenoldopamNisoldipine may increase the hypotensive activities of Fenoldopam.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nisoldipine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nisoldipine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nisoldipine.
FluconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nisoldipine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nisoldipine.
FluvoxamineThe metabolism of Nisoldipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Nisoldipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Fosaprepitant.
FosinoprilNisoldipine may increase the hypotensive activities of Fosinopril.
FosphenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nisoldipine.
FurazolidoneFurazolidone may increase the hypotensive activities of Nisoldipine.
FurosemideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.
Fusidic AcidThe serum concentration of Nisoldipine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nisoldipine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nisoldipine.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nisoldipine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nisoldipine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nisoldipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nisoldipine.
GuanabenzNisoldipine may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Nisoldipine.
GuanethidineNisoldipine may increase the hypotensive activities of Guanethidine.
GuanfacineNisoldipine may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Nisoldipine.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nisoldipine.
HexamethoniumNisoldipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nisoldipine.
HexobarbitalHexobarbital may increase the hypotensive activities of Nisoldipine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Nisoldipine.
HydralazineNisoldipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideNisoldipine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nisoldipine.
HydroflumethiazideNisoldipine may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nisoldipine.
IdelalisibThe serum concentration of Nisoldipine can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Nisoldipine.
ImatinibThe metabolism of Nisoldipine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nisoldipine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nisoldipine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nisoldipine.
IndapamideNisoldipine may increase the hypotensive activities of Indapamide.
IndenololNisoldipine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Nisoldipine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Nisoldipine.
IndoraminNisoldipine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Nisoldipine.
IproniazidIproniazid may increase the hypotensive activities of Nisoldipine.
IrbesartanNisoldipine may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nisoldipine.
IsavuconazoniumThe metabolism of Nisoldipine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nisoldipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nisoldipine.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Nisoldipine.
ItraconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Nisoldipine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nisoldipine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nisoldipine.
KetoconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Ketoconazole.
LabetalolNisoldipine may increase the hypotensive activities of Labetalol.
LacidipineNisoldipine may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nisoldipine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nisoldipine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nisoldipine.
LatanoprostNisoldipine may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nisoldipine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nisoldipine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nisoldipine.
LercanidipineNisoldipine may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nisoldipine.
LevobunololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levobunolol.
LevodopaNisoldipine may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nisoldipine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nisoldipine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nisoldipine.
LisinoprilNisoldipine may increase the hypotensive activities of Lisinopril.
LofexidineNisoldipine may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nisoldipine.
LopinavirThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.
LosartanNisoldipine may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Nisoldipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Luliconazole.
MacitentanNisoldipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium Sulfate.
ManidipineNisoldipine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mannitol.
MebanazineMebanazine may increase the hypotensive activities of Nisoldipine.
MecamylamineNisoldipine may increase the hypotensive activities of Mecamylamine.
MethazolamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Nisoldipine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nisoldipine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.
MethyldopaNisoldipine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Nisoldipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nisoldipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nisoldipine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine.
MetipranololNisoldipine may increase the hypotensive activities of Metipranolol.
MetolazoneNisoldipine may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Nisoldipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nisoldipine.
MibefradilNisoldipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nisoldipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nisoldipine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nisoldipine.
MifepristoneThe metabolism of Nisoldipine can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nisoldipine.
MinaprineMinaprine may increase the hypotensive activities of Nisoldipine.
MinoxidilMinoxidil may increase the hypotensive activities of Nisoldipine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nisoldipine.
MitotaneThe serum concentration of Nisoldipine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nisoldipine.
MivacuriumNisoldipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Nisoldipine.
ModafinilThe serum concentration of Nisoldipine can be decreased when it is combined with Modafinil.
MoexiprilNisoldipine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Nisoldipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nisoldipine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Nisoldipine.
MoxonidineNisoldipine may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nisoldipine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nisoldipine.
NadololNisoldipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Nisoldipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nisoldipine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nisoldipine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nisoldipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nisoldipine.
NebivololNisoldipine may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir.
NesiritideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nesiritide.
NetupitantThe serum concentration of Nisoldipine can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nisoldipine can be decreased when it is combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Nisoldipine.
NicardipineNisoldipine may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Nisoldipine.
NifedipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nifedipine.
NiguldipineNisoldipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Nisoldipine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nisoldipine.
NilvadipineNisoldipine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Nisoldipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nisoldipine.
NitrendipineNisoldipine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitroglycerin.
NitroprussideNisoldipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nisoldipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nisoldipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nisoldipine.
ObinutuzumabNisoldipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Nisoldipine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nisoldipine.
OlaparibThe metabolism of Nisoldipine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Nisoldipine.
OmapatrilatNisoldipine may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nisoldipine.
OsimertinibThe serum concentration of Nisoldipine can be increased when it is combined with Osimertinib.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nisoldipine.
OxprenololNisoldipine may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nisoldipine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nisoldipine.
PalbociclibThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nisoldipine.
PapaverineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.
PargylineNisoldipine may increase the hypotensive activities of Pargyline.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.
PenbutololNisoldipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nisoldipine.
PentobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital.
PentoliniumNisoldipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nisoldipine.
PerindoprilNisoldipine may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Nisoldipine.
PheniprazinePheniprazine may increase the hypotensive activities of Nisoldipine.
PhenobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Nisoldipine.
PhenoxybenzamineNisoldipine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nisoldipine.
PhentolamineNisoldipine may increase the hypotensive activities of Phentolamine.
PhenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nisoldipine.
PinacidilNisoldipine may increase the hypotensive activities of Pinacidil.
PindololNisoldipine may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Nisoldipine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nisoldipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Nisoldipine.
PolythiazideNisoldipine may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nisoldipine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nisoldipine.
PosaconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.
PrazosinNisoldipine may increase the hypotensive activities of Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nisoldipine.
PrimidoneThe serum concentration of Nisoldipine can be decreased when it is combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Nisoldipine.
PropranololNisoldipine may increase the hypotensive activities of Propranolol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nisoldipine.
QuetiapineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.
QuinaprilNisoldipine may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Nisoldipine.
QuinineQuinine may increase the hypotensive activities of Nisoldipine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Nisoldipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nisoldipine.
RamiprilRamipril may increase the hypotensive activities of Nisoldipine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nisoldipine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nisoldipine.
RanolazineThe metabolism of Nisoldipine can be decreased when combined with Ranolazine.
RapacuroniumNisoldipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Nisoldipine.
RemikirenRemikiren may increase the hypotensive activities of Nisoldipine.
RescinnamineNisoldipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Nisoldipine.
RifabutinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Nisoldipine.
RifapentineThe serum concentration of Nisoldipine can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nisoldipine.
RiociguatNisoldipine may increase the hypotensive activities of Riociguat.
RisperidoneNisoldipine may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Nisoldipine can be increased when it is combined with Ritonavir.
RituximabNisoldipine may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nisoldipine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nisoldipine.
SafrazineSafrazine may increase the hypotensive activities of Nisoldipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nisoldipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nisoldipine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Nisoldipine.
SaprisartanNisoldipine may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.
SecobarbitalSecobarbital may increase the hypotensive activities of Nisoldipine.
SelegilineSelegiline may increase the hypotensive activities of Nisoldipine.
SelexipagNisoldipine may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nisoldipine.
SildenafilSildenafil may increase the antihypertensive activities of Nisoldipine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.
SilodosinSilodosin may increase the hypotensive activities of Nisoldipine.
SiltuximabThe serum concentration of Nisoldipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nisoldipine can be increased when it is combined with Simeprevir.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nisoldipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nisoldipine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nisoldipine.
SitaxentanNisoldipine may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nisoldipine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nisoldipine.
SotalolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nisoldipine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nisoldipine.
SpiraprilNisoldipine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone.
St. John's WortThe serum concentration of Nisoldipine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Nisoldipine can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nisoldipine.
SulfisoxazoleThe metabolism of Nisoldipine can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nisoldipine.
TadalafilTadalafil may increase the antihypertensive activities of Nisoldipine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nisoldipine.
TamsulosinTamsulosin may increase the hypotensive activities of Nisoldipine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nisoldipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nisoldipine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nisoldipine.
TelaprevirThe serum concentration of Nisoldipine can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Telithromycin.
TelmisartanNisoldipine may increase the hypotensive activities of Telmisartan.
TemocaprilNisoldipine may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nisoldipine.
TerazosinTerazosin may increase the hypotensive activities of Nisoldipine.
TerazosinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Terazosin.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nisoldipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nisoldipine.
TerlipressinNisoldipine may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Nisoldipine.
ThiopentalThiopental may increase the hypotensive activities of Nisoldipine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nisoldipine.
TiboloneNisoldipine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nisoldipine.
TiclopidineThe metabolism of Nisoldipine can be decreased when combined with Ticlopidine.
TicrynafenNisoldipine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Nisoldipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nisoldipine.
TizanidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Tizanidine.
TocilizumabThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.
TolazolineNisoldipine may increase the hypotensive activities of Tolazoline.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nisoldipine.
ToloxatoneToloxatone may increase the hypotensive activities of Nisoldipine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nisoldipine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nisoldipine.
TorasemideTorasemide may increase the hypotensive activities of Nisoldipine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Nisoldipine.
TrandolaprilNisoldipine may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nisoldipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nisoldipine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nisoldipine.
TravoprostTravoprost may increase the hypotensive activities of Nisoldipine.
TreprostinilTreprostinil may increase the hypotensive activities of Nisoldipine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.
TrichlormethiazideNisoldipine may increase the hypotensive activities of Trichlormethiazide.
TrimazosinNisoldipine may increase the hypotensive activities of Trimazosin.
TrimethaphanNisoldipine may increase the hypotensive activities of Trimethaphan.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nisoldipine.
UdenafilUdenafil may increase the antihypertensive activities of Nisoldipine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nisoldipine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nisoldipine.
UnoprostoneNisoldipine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Nisoldipine.
VardenafilVardenafil may increase the antihypertensive activities of Nisoldipine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nisoldipine.
VenlafaxineThe metabolism of Nisoldipine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Nisoldipine.
VerapamilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Verapamil.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nisoldipine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nisoldipine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nisoldipine.
VoriconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Voriconazole.
XylometazolineNisoldipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Nisoldipine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nisoldipine.
ZiprasidoneThe metabolism of Nisoldipine can be decreased when combined with Ziprasidone.
Food Interactions
  • Do not take with grapefruit juice as this has been shown to interfere with nisoldipine metabolism, resulting in a mean increase in Cmax of about 3-fold (up to about 7-fold) and AUC of almost 2-fold (up to 5-fold).

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hu H, Marban E: Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol Pharmacol. 1998 May;53(5):902-7. [PubMed:9584217 ]
  3. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  4. Wei X, Pan S, Lang W, Kim H, Schneider T, Perez-Reyes E, Birnbaumer L: Molecular determinants of cardiac Ca2+ channel pharmacology. Subunit requirement for the high affinity and allosteric regulation of dihydropyridine binding. J Biol Chem. 1995 Nov 10;270(45):27106-11. [PubMed:7592963 ]
  5. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23